Concepts (248)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diet, Mediterranean | 4 | 2024 | 12 | 1.140 |
Why?
|
| Cognition Disorders | 8 | 2010 | 175 | 1.020 |
Why?
|
| Humans | 43 | 2024 | 2957 | 0.900 |
Why?
|
| Diet | 11 | 2018 | 36 | 0.810 |
Why?
|
| Female | 35 | 2024 | 1724 | 0.800 |
Why?
|
| Dietary Fats | 5 | 2024 | 14 | 0.760 |
Why?
|
| Dementia | 3 | 2014 | 73 | 0.710 |
Why?
|
| Male | 31 | 2024 | 1860 | 0.660 |
Why?
|
| Alzheimer Disease | 7 | 2014 | 250 | 0.620 |
Why?
|
| Aged | 22 | 2024 | 956 | 0.600 |
Why?
|
| Diet Surveys | 4 | 2017 | 9 | 0.600 |
Why?
|
| Middle Aged | 18 | 2018 | 792 | 0.590 |
Why?
|
| Blood Viscosity | 5 | 2003 | 6 | 0.560 |
Why?
|
| Nutrition Assessment | 4 | 2017 | 18 | 0.540 |
Why?
|
| Folic Acid | 5 | 2009 | 10 | 0.500 |
Why?
|
| Trans Fatty Acids | 2 | 2014 | 4 | 0.480 |
Why?
|
| Dietary Supplements | 5 | 2011 | 16 | 0.480 |
Why?
|
| Fatty Acids | 2 | 2014 | 6 | 0.480 |
Why?
|
| Cognitive Dysfunction | 3 | 2024 | 165 | 0.470 |
Why?
|
| Lipoproteins | 2 | 2010 | 3 | 0.460 |
Why?
|
| Postprandial Period | 2 | 2010 | 3 | 0.460 |
Why?
|
| Liver Diseases | 1 | 2015 | 2 | 0.450 |
Why?
|
| Liver Transplantation | 1 | 2015 | 3 | 0.450 |
Why?
|
| Energy Metabolism | 1 | 2015 | 6 | 0.450 |
Why?
|
| Hypertriglyceridemia | 3 | 2010 | 3 | 0.430 |
Why?
|
| Apolipoprotein E4 | 4 | 2024 | 76 | 0.420 |
Why?
|
| Feeding Behavior | 6 | 2017 | 18 | 0.420 |
Why?
|
| Hypercholesterolemia | 5 | 2005 | 6 | 0.410 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2011 | 50 | 0.390 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 5 | 2005 | 7 | 0.370 |
Why?
|
| Adult | 14 | 2018 | 794 | 0.360 |
Why?
|
| Folic Acid Deficiency | 2 | 2009 | 2 | 0.360 |
Why?
|
| Vitamins | 1 | 2011 | 3 | 0.340 |
Why?
|
| Fenofibrate | 1 | 2010 | 1 | 0.330 |
Why?
|
| Hypolipidemic Agents | 1 | 2010 | 2 | 0.330 |
Why?
|
| Metabolic Syndrome | 1 | 2010 | 5 | 0.330 |
Why?
|
| Vitamin B Complex | 2 | 2011 | 3 | 0.330 |
Why?
|
| Vitamin E | 6 | 2011 | 13 | 0.330 |
Why?
|
| Homocysteine | 2 | 2007 | 3 | 0.310 |
Why?
|
| Triglycerides | 4 | 2010 | 11 | 0.300 |
Why?
|
| Vitamin B 12 Deficiency | 1 | 2009 | 1 | 0.290 |
Why?
|
| Aged, 80 and over | 10 | 2024 | 567 | 0.290 |
Why?
|
| Chicago | 8 | 2024 | 160 | 0.270 |
Why?
|
| Lipoproteins, LDL | 2 | 2005 | 2 | 0.260 |
Why?
|
| Hyperhomocysteinemia | 1 | 2006 | 2 | 0.250 |
Why?
|
| Diagnostic Errors | 1 | 2006 | 5 | 0.250 |
Why?
|
| Coronary Disease | 2 | 2002 | 5 | 0.220 |
Why?
|
| Dietary Approaches To Stop Hypertension | 1 | 2024 | 5 | 0.220 |
Why?
|
| Surveys and Questionnaires | 8 | 2016 | 142 | 0.210 |
Why?
|
| Cross-Sectional Studies | 4 | 2017 | 105 | 0.210 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 1 | 2004 | 1 | 0.210 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2004 | 4 | 0.210 |
Why?
|
| Alleles | 1 | 2024 | 65 | 0.200 |
Why?
|
| Risk Factors | 6 | 2024 | 275 | 0.200 |
Why?
|
| Reproducibility of Results | 3 | 2017 | 83 | 0.200 |
Why?
|
| Longitudinal Studies | 6 | 2024 | 260 | 0.190 |
Why?
|
| Vitamin B 12 | 3 | 2009 | 8 | 0.190 |
Why?
|
| Arteriosclerosis | 2 | 2004 | 3 | 0.180 |
Why?
|
| Cohort Studies | 5 | 2010 | 233 | 0.180 |
Why?
|
| Fibrinogen | 3 | 2002 | 5 | 0.180 |
Why?
|
| Cholesterol | 4 | 2014 | 18 | 0.180 |
Why?
|
| Young Adult | 3 | 2018 | 187 | 0.180 |
Why?
|
| Lipids | 3 | 2005 | 13 | 0.170 |
Why?
|
| Seafood | 2 | 2016 | 6 | 0.170 |
Why?
|
| Anticholesteremic Agents | 2 | 1999 | 2 | 0.160 |
Why?
|
| Double-Blind Method | 4 | 2010 | 46 | 0.160 |
Why?
|
| Simvastatin | 4 | 2005 | 5 | 0.150 |
Why?
|
| Body Mass Index | 2 | 2017 | 64 | 0.150 |
Why?
|
| Pravastatin | 5 | 2005 | 5 | 0.150 |
Why?
|
| Fatty Acids, Omega-3 | 3 | 2016 | 7 | 0.150 |
Why?
|
| Nutritional Status | 2 | 2011 | 18 | 0.150 |
Why?
|
| Nutrition Policy | 2 | 2010 | 3 | 0.150 |
Why?
|
| Antioxidants | 3 | 2005 | 17 | 0.150 |
Why?
|
| Cholesterol, LDL | 2 | 2010 | 4 | 0.140 |
Why?
|
| Hypertension | 1 | 2018 | 13 | 0.130 |
Why?
|
| Cognition | 3 | 2024 | 220 | 0.130 |
Why?
|
| Telemedicine | 1 | 2018 | 14 | 0.130 |
Why?
|
| Exercise | 1 | 2018 | 33 | 0.130 |
Why?
|
| Health Promotion | 1 | 2018 | 25 | 0.130 |
Why?
|
| Risk | 3 | 2014 | 44 | 0.130 |
Why?
|
| Nutritive Value | 1 | 2017 | 2 | 0.130 |
Why?
|
| Food | 1 | 2017 | 4 | 0.130 |
Why?
|
| Choice Behavior | 1 | 2017 | 5 | 0.130 |
Why?
|
| Diet, Western | 1 | 2017 | 2 | 0.130 |
Why?
|
| United States | 1 | 2017 | 243 | 0.120 |
Why?
|
| End Stage Liver Disease | 1 | 2015 | 2 | 0.110 |
Why?
|
| Calorimetry, Indirect | 1 | 2015 | 3 | 0.110 |
Why?
|
| Rest | 1 | 2015 | 8 | 0.110 |
Why?
|
| Dietary Fats, Unsaturated | 1 | 2014 | 1 | 0.110 |
Why?
|
| Blood-Brain Barrier | 1 | 2014 | 7 | 0.110 |
Why?
|
| Brain | 2 | 2014 | 202 | 0.100 |
Why?
|
| Peritoneal Dialysis | 1 | 2014 | 1 | 0.100 |
Why?
|
| Nutrition Therapy | 1 | 2014 | 2 | 0.100 |
Why?
|
| Renal Dialysis | 1 | 2014 | 2 | 0.100 |
Why?
|
| Severity of Illness Index | 2 | 2010 | 97 | 0.100 |
Why?
|
| Docosahexaenoic Acids | 2 | 2011 | 4 | 0.100 |
Why?
|
| Animals | 2 | 2014 | 1050 | 0.100 |
Why?
|
| Anemia, Sickle Cell | 1 | 1992 | 3 | 0.100 |
Why?
|
| Depression | 1 | 2013 | 59 | 0.090 |
Why?
|
| Indicators and Reagents | 2 | 2009 | 4 | 0.090 |
Why?
|
| Epidemiologic Studies | 1 | 2011 | 6 | 0.080 |
Why?
|
| Research Design | 1 | 2011 | 21 | 0.080 |
Why?
|
| Wine | 1 | 2010 | 2 | 0.080 |
Why?
|
| Cholesterol, VLDL | 1 | 2010 | 1 | 0.080 |
Why?
|
| Cholesterol, HDL | 1 | 2010 | 4 | 0.080 |
Why?
|
| Patient Compliance | 1 | 2010 | 13 | 0.080 |
Why?
|
| Placebos | 1 | 2010 | 7 | 0.080 |
Why?
|
| Biomarkers | 2 | 2009 | 101 | 0.080 |
Why?
|
| Memory | 1 | 2010 | 48 | 0.080 |
Why?
|
| Ascorbic Acid | 2 | 2002 | 15 | 0.080 |
Why?
|
| Prospective Studies | 5 | 2014 | 203 | 0.080 |
Why?
|
| Blood Chemical Analysis | 2 | 2006 | 8 | 0.070 |
Why?
|
| Age Factors | 4 | 2018 | 89 | 0.070 |
Why?
|
| Methylmalonic Acid | 1 | 2009 | 1 | 0.070 |
Why?
|
| Energy Intake | 3 | 2017 | 24 | 0.070 |
Why?
|
| Neuropsychological Tests | 4 | 2016 | 238 | 0.070 |
Why?
|
| Follow-Up Studies | 4 | 2016 | 147 | 0.070 |
Why?
|
| Carotenoids | 2 | 2002 | 3 | 0.070 |
Why?
|
| Chromatography | 1 | 1988 | 1 | 0.070 |
Why?
|
| Contraceptives, Oral | 2 | 1978 | 2 | 0.070 |
Why?
|
| Time Factors | 3 | 2013 | 208 | 0.060 |
Why?
|
| Food Analysis | 1 | 2007 | 1 | 0.060 |
Why?
|
| Specimen Handling | 1 | 2006 | 4 | 0.060 |
Why?
|
| Vitamin B 6 | 1 | 2006 | 3 | 0.060 |
Why?
|
| Copper | 1 | 2006 | 11 | 0.060 |
Why?
|
| Fruit | 2 | 2017 | 3 | 0.060 |
Why?
|
| Vegetables | 2 | 2017 | 3 | 0.060 |
Why?
|
| Beverages | 2 | 2017 | 4 | 0.060 |
Why?
|
| Fish Products | 1 | 2005 | 2 | 0.060 |
Why?
|
| Fishes | 1 | 2005 | 2 | 0.060 |
Why?
|
| Growth | 1 | 2005 | 3 | 0.060 |
Why?
|
| Ketone Bodies | 1 | 2005 | 3 | 0.060 |
Why?
|
| Child Nutritional Physiological Phenomena | 1 | 2005 | 4 | 0.060 |
Why?
|
| Epilepsy | 1 | 2005 | 9 | 0.060 |
Why?
|
| Ketosis | 1 | 2005 | 5 | 0.060 |
Why?
|
| Food, Fortified | 1 | 2005 | 3 | 0.060 |
Why?
|
| Child Development | 1 | 2005 | 12 | 0.060 |
Why?
|
| Bone Remodeling | 1 | 2005 | 38 | 0.060 |
Why?
|
| Tocopherols | 1 | 2005 | 3 | 0.060 |
Why?
|
| Chemokine CCL2 | 1 | 2005 | 17 | 0.050 |
Why?
|
| Hyperlipoproteinemias | 1 | 2004 | 1 | 0.050 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2004 | 1 | 0.050 |
Why?
|
| Adolescent | 3 | 2018 | 247 | 0.050 |
Why?
|
| Incidence | 3 | 2013 | 110 | 0.050 |
Why?
|
| Genotype | 1 | 2024 | 85 | 0.050 |
Why?
|
| Nutrition Disorders | 1 | 2003 | 2 | 0.050 |
Why?
|
| Drinking | 1 | 2003 | 1 | 0.050 |
Why?
|
| Hemorheology | 1 | 2003 | 1 | 0.050 |
Why?
|
| Sex Factors | 2 | 2018 | 72 | 0.050 |
Why?
|
| Vitamin A | 1 | 2002 | 2 | 0.050 |
Why?
|
| Sampling Studies | 1 | 2002 | 3 | 0.050 |
Why?
|
| Probability | 1 | 2002 | 7 | 0.050 |
Why?
|
| Regression Analysis | 1 | 2002 | 27 | 0.050 |
Why?
|
| Sensitivity and Specificity | 1 | 2002 | 74 | 0.040 |
Why?
|
| Contraceptives, Oral, Combined | 2 | 1978 | 2 | 0.040 |
Why?
|
| Kidney Failure, Chronic | 1 | 2001 | 5 | 0.040 |
Why?
|
| Analysis of Variance | 1 | 2001 | 30 | 0.040 |
Why?
|
| Diabetes Mellitus | 1 | 2001 | 10 | 0.040 |
Why?
|
| Clinical Trials as Topic | 1 | 2001 | 27 | 0.040 |
Why?
|
| Inflammation Mediators | 1 | 1999 | 4 | 0.040 |
Why?
|
| Cytokines | 1 | 1999 | 33 | 0.040 |
Why?
|
| Estrogen Replacement Therapy | 1 | 1998 | 1 | 0.040 |
Why?
|
| Postmenopause | 1 | 1998 | 4 | 0.040 |
Why?
|
| Cardiovascular Diseases | 1 | 1998 | 44 | 0.030 |
Why?
|
| Internet | 1 | 2018 | 8 | 0.030 |
Why?
|
| Health Behavior | 1 | 2018 | 16 | 0.030 |
Why?
|
| Life Style | 1 | 2018 | 19 | 0.030 |
Why?
|
| Contraceptive Agents, Female | 1 | 1977 | 1 | 0.030 |
Why?
|
| Mestranol | 1 | 1977 | 1 | 0.030 |
Why?
|
| Norethindrone | 1 | 1977 | 1 | 0.030 |
Why?
|
| Blood | 1 | 1977 | 3 | 0.030 |
Why?
|
| Research | 1 | 1977 | 6 | 0.030 |
Why?
|
| Diet Records | 1 | 2017 | 2 | 0.030 |
Why?
|
| Family Characteristics | 1 | 2017 | 3 | 0.030 |
Why?
|
| Lovastatin | 1 | 1996 | 1 | 0.030 |
Why?
|
| Platelet Aggregation | 1 | 1996 | 3 | 0.030 |
Why?
|
| Neuroprotection | 1 | 2016 | 2 | 0.030 |
Why?
|
| Genotyping Techniques | 1 | 2016 | 6 | 0.030 |
Why?
|
| Gene-Environment Interaction | 1 | 2016 | 9 | 0.030 |
Why?
|
| Linear Models | 1 | 2016 | 39 | 0.030 |
Why?
|
| Heterozygote | 1 | 2016 | 48 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2005 | 85 | 0.030 |
Why?
|
| Logistic Models | 2 | 2005 | 60 | 0.030 |
Why?
|
| Dietary Fiber | 1 | 2014 | 4 | 0.030 |
Why?
|
| Models, Statistical | 2 | 2005 | 27 | 0.030 |
Why?
|
| Geriatric Assessment | 1 | 2013 | 38 | 0.020 |
Why?
|
| Models, Biological | 1 | 2013 | 110 | 0.020 |
Why?
|
| Lung Neoplasms | 1 | 1992 | 25 | 0.020 |
Why?
|
| beta Carotene | 2 | 2002 | 4 | 0.020 |
Why?
|
| Chemistry | 1 | 1988 | 1 | 0.020 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 1988 | 1 | 0.020 |
Why?
|
| Dehydroascorbic Acid | 1 | 1988 | 1 | 0.020 |
Why?
|
| Drug Stability | 1 | 1988 | 1 | 0.020 |
Why?
|
| 2,3-Diketogulonic Acid | 1 | 1988 | 1 | 0.020 |
Why?
|
| Chemical Phenomena | 1 | 1988 | 2 | 0.020 |
Why?
|
| Eating | 1 | 2005 | 4 | 0.010 |
Why?
|
| Educational Status | 1 | 2005 | 41 | 0.010 |
Why?
|
| Alkaline Phosphatase | 1 | 2005 | 11 | 0.010 |
Why?
|
| Collagen | 1 | 2005 | 24 | 0.010 |
Why?
|
| Osteocalcin | 1 | 2005 | 19 | 0.010 |
Why?
|
| Body Height | 1 | 2005 | 3 | 0.010 |
Why?
|
| Nutritional Requirements | 1 | 2005 | 8 | 0.010 |
Why?
|
| Data Collection | 1 | 2005 | 7 | 0.010 |
Why?
|
| Motor Activity | 1 | 2005 | 53 | 0.010 |
Why?
|
| Body Weight | 1 | 2005 | 34 | 0.010 |
Why?
|
| alpha-Tocopherol | 1 | 2005 | 3 | 0.010 |
Why?
|
| gamma-Tocopherol | 1 | 2005 | 3 | 0.010 |
Why?
|
| Confidence Intervals | 1 | 2005 | 13 | 0.010 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2005 | 11 | 0.010 |
Why?
|
| Oxidation-Reduction | 1 | 2005 | 13 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2005 | 119 | 0.010 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type I | 1 | 2004 | 1 | 0.010 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type II | 1 | 2004 | 1 | 0.010 |
Why?
|
| Tumor Necrosis Factor Decoy Receptors | 1 | 2004 | 1 | 0.010 |
Why?
|
| Infant | 1 | 2005 | 122 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2005 | 167 | 0.010 |
Why?
|
| Child | 1 | 2005 | 197 | 0.010 |
Why?
|
| Aging | 1 | 2006 | 204 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2005 | 186 | 0.010 |
Why?
|
| Eicosapentaenoic Acid | 1 | 2003 | 3 | 0.010 |
Why?
|
| Fatty Acids, Unsaturated | 1 | 2003 | 4 | 0.010 |
Why?
|
| Hematocrit | 1 | 2003 | 1 | 0.010 |
Why?
|
| Elasticity | 1 | 2003 | 11 | 0.010 |
Why?
|
| Fasting | 1 | 2003 | 5 | 0.010 |
Why?
|
| Reference Values | 1 | 2003 | 28 | 0.010 |
Why?
|
| Fluid Therapy | 1 | 2003 | 12 | 0.010 |
Why?
|
| Psychological Tests | 1 | 2002 | 4 | 0.010 |
Why?
|
| Cluster Analysis | 1 | 2002 | 10 | 0.010 |
Why?
|
| Population Surveillance | 1 | 2002 | 14 | 0.010 |
Why?
|
| Oxidative Stress | 1 | 2002 | 13 | 0.010 |
Why?
|
| Apolipoproteins E | 1 | 2002 | 34 | 0.010 |
Why?
|
| Receptors, Interleukin-1 | 1 | 1999 | 1 | 0.010 |
Why?
|
| Interleukin-8 | 1 | 1999 | 4 | 0.010 |
Why?
|
| Interleukin-1 | 1 | 1999 | 9 | 0.010 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 1999 | 30 | 0.010 |
Why?
|
| Interleukin-6 | 1 | 1999 | 21 | 0.010 |
Why?
|
| Medroxyprogesterone | 1 | 1998 | 1 | 0.010 |
Why?
|
| Estradiol | 1 | 1998 | 3 | 0.010 |
Why?
|
| Hemolysis | 1 | 1978 | 1 | 0.010 |
Why?
|
| Spectrophotometry | 1 | 1978 | 1 | 0.010 |
Why?
|
| Biology | 1 | 1977 | 1 | 0.010 |
Why?
|
| Contraception | 1 | 1977 | 1 | 0.010 |
Why?
|
| Contraceptive Agents | 1 | 1977 | 1 | 0.010 |
Why?
|
| Contraceptives, Oral, Hormonal | 1 | 1977 | 1 | 0.010 |
Why?
|
| Family Planning Services | 1 | 1977 | 1 | 0.010 |
Why?
|
| Norethynodrel | 1 | 1977 | 1 | 0.010 |
Why?
|
| Physiology | 1 | 1977 | 2 | 0.010 |
Why?
|
| Smoking | 1 | 1992 | 28 | 0.010 |
Why?
|